Reaction

Streptococcal Sepsis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,178 reports · 56 co-occurring drugs

As of the last recalculation, Streptococcal Sepsis appears in 1,178 FAERS reports alongside 56 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 114.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ado-Trastuzumab Emtansine	52	114.0	114.7
Bleomycin Sulfate	48	85.5	85.9
Carboxymethylcellulose Sodium	42	81.8	82.2
Dronabinol	34	76.9	77.2
Lapatinib	57	68.2	68.4
Fam-Trastuzumab Deruxtecan-Nxki	27	48.4	48.5
Fosaprepitant Dimeglumine	34	45.0	45.1
Pertuzumab	57	38.9	39.0
Aprepitant	35	34.5	34.6
Fulvestrant	58	32.6	32.6
Trazodone Hydrochloride	28	32.4	32.4
Doxorubicin Hydrochloride	56	31.8	31.8
Cytarabine	84	26.5	26.6
Lactulose	51	24.5	24.6
Thiotepa	12	22.4	22.4
Sirolimus	16	21.3	21.3
Cefepime Hydrochloride	19	21.2	21.2
Filgrastim	43	20.9	20.9
Cefepime	15	18.7	18.7
Busulfan	16	18.2	18.2
Fludarabine Phosphate	37	17.1	17.1
Amphotericin B	12	17.1	17.1
Trastuzumab	61	16.5	16.5
Enoxaparin Sodium	51	16.3	16.3
Levofloxacin	52	15.9	15.9
Levofloxacin In 5% Dextrose	52	15.9	15.9
Micafungin Sodium	7	14.7	14.7
Misoprostol	8	14.6	14.6
Pegaspargase	10	14.5	14.6
Magnesium Sulfate In Water For	10	13.9	14.0
Erythropoietin	16	13.9	13.9
Magnesium Sulfate Heptahydrate	10	13.7	13.7
Capecitabine	67	13.7	13.7
Magnesium Sulfate	10	13.6	13.7
Mesna Injection	6	12.9	12.9
Fentanyl	68	12.9	12.9
Mesna	6	12.7	12.7
Etoposide	48	12.0	12.0
Granisetron Hydrochloride	7	11.9	11.9
Nevirapine	6	11.8	11.8
Heparin Sodium	9	11.6	11.7
Melphalan Hydrochloride	16	11.4	11.4
Cladribine	6	11.1	11.1
Doxorubicin	52	10.7	10.7
Hydromorphone Hydrochloride	53	10.6	10.6
Granisetron	6	10.2	10.2
Docetaxel Anhydrous	37	10.0	10.0
Docetaxel	37	10.0	10.0
Brentuximab Vedotin	5	8.7	8.7
Ifosfamide	10	8.3	8.3
Sofosbuvir	8	7.2	7.2
Pegfilgrastim	36	6.6	6.6
Venetoclax	21	6.1	6.1
Acalabrutinib	4	5.8	5.8
Denosumab	64	5.8	5.8
Axicabtagene Ciloleucel	3	5.4	5.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.